Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension
In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Prevention, Statins, Acute Heart Failure, Hypertension, Sleep Apnea, Acute Coronary Syndromes, Pulmonary Hypertension and Venous Thromboembolism
Keywords: Carvedilol, Heart Failure, Body Mass Index, Sedentary Behavior, Sleep, Healthy Lifestyle, Alcohol Drinking, Life Style, Heart Disease Risk Factors, Primary Prevention, Angiotensin Receptor Antagonists, Amiloride, Thiazides, Calcium Channel Blockers, Blood Pressure, Hypertension, Spironolactone, EaglesEyeView
